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Role of Estrogen Response Element in the Human
Prolactin Gene: Transcriptional Response and Timing
Anne V. McNamara, Antony D. Adamson, Lee S. S. Dunham, Sabrina Semprini,
David G. Spiller, Alan S. McNeilly, John J. Mullins, Julian R. E. Davis,
and Michael R. H. White
Systems Microscopy Centre (A.V.M., A.D.A., D.G.S., M.R.H.W.), Faculty of Life Sciences, and Faculty of
Medical and Human Sciences (L.S.S.D., J.R.E.D.), Centre for Endocrinology and Diabetes, Institute of
Human Development, University of Manchester, Manchester M13 9PT, United Kingdom; and The
Molecular Physiology Group (S.S., J.J.M.), Centre for Cardiovascular Science, and Medical Research
Council Human Reproductive Sciences Unit (A.S.M.), Centre for Reproductive Biology, Queen’s Medical
Research Institute, Edinburgh EH16 4TJ, United Kingdom
The use of bacterial artificial chromosome (BAC) reporter constructs in molecular physiology
enables the inclusion of large sections of flanking DNA, likely to contain regulatory elements and
enhancers regions that contribute to the transcriptional output of a gene. Using BAC recom-
bineering, we have manipulated a 160-kb human prolactin luciferase (hPRL-Luc) BAC construct
and mutated the previously defined proximal estrogen response element (ERE) located1189 bp
relative to the transcription start site, to assess its involvement in the estrogen responsiveness of
the entire hPRL locus. We found that GH3 cell lines stably expressing Luc under control of the
ERE-mutated hPRL promoter (ERE-Mut) displayed a dramatically reduced transcriptional response
to 17-estradiol (E2) treatment compared with cells expressing Luc from the wild-type (WT) ERE
hPRL-Luc promoter (ERE-WT). The 1189 ERE controls not only the response to E2 treatment but
also the acute transcriptional response to TNF, which was abolished in ERE-Mut cells. ERE-WT
cells displayed a biphasic transcriptional response after TNF treatment, the acute phase of which
was blocked after treatment with the estrogen receptor antagonist 4-hydroxy-tamoxifen. Unex-
pectedly, we show the oscillatory characteristics of hPRL promoter activity in individual living cells
were unaffected by disruption of this crucial response element, real-time bioluminescence imaging
showed that transcription cycles weremaintained, with similar cycle lengths, in ERE-WT and ERE-Mut
cells. These data suggest the 1189 ERE is the dominant response element involved in the hPRL
transcriptional response to both E2 and TNF and, crucially, that cycles of hPRL promoter activity are
independent of estrogen receptor binding. (Molecular Endocrinology 30: 189–200, 2016)
Prolactin (PRL) is a polypeptide hormone primarilyproduced by the lactotroph cells of the anterior pitu-
itary. It is also expressed in humans and primates at ex-
trapituitary sites, including the endometrium and in im-
mune tissues (1–4), and has been reported to have a wide
range of biological actions (5). PRL expression and secre-
tion from lactotroph cells is subject to both acute and
long-term regulation by multiple hormone signals, in-
cluding hypothalamic TRH, dopamine, and second mes-
sengers Ca2 and cAMP (6).
Estrogen is a well-known stimulus to pituitary PRL
gene expression in rodents and in man (7–11). Estrogen-
induced gene expression is mediated by the actions of the
2 estrogen receptors (ERs), ER and ER. These ligand-
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activated transcription factors regulate gene expression
through direct binding to estrogen response elements
(EREs) in the DNA of target promoters or indirectly by
binding to DNA-bound transcription factors such as ac-
tivating protein 1 (AP-1) and specificity protein 1 (Sp1).
Once bound, the ER then facilitates recruitment of co-
regulator proteins to the promoter to influence transcrip-
tional activity (12–15). ER signaling can also be activated
in the absence of ligand by a growing number of growth
factors and cytokines, including epidermal growth factor,
fibroblast growth factor 2 (FGF-2), and TNF, which
trigger signal transduction pathways such as ERK and
MAPK that can phosphorylate and activate ER in the
absence of ligand (16–18). Additionally, targeted dele-
tion of ER (ERKO) in mice leads to reduced lactotroph
cell numbers and a dramatic reduction in pituitary PRL
mRNA (19).
Cyclical recruitment of ER to the promoter regions of
estrogen-responsive genes has been reported in several
systems (12, 17, 20). Furthermore, ER-binding sites can
be situated at long-range to the transcription start site of
the genes they regulate. Binding of ER to distal response
elements promotes similar behavior to that at proximal
elements, with recruitment of coregulators to influence
chromatin structure and transcriptional activity. Long-
range chromatin interactions between ERs bound at dis-
tal response elements and those located in the proximal
regions of estrogen-regulated genes has also been re-
ported (21–23).
In the human PRL (hPRL) gene promoter we have
previously characterized a variant ERE 1189 bp upstream
from the transcription start site which confers modest
transcriptional induction on reporter gene expression af-
ter estrogen stimulation in cultured GH3 pituitary cells
expressing luciferase (Luc) under the control of a 5-kb
hPRL promoter fragment (9). In contrast, GH3 cells sta-
bly transfected with a bacterial artificial chromosome
(BAC) construct expressing Luc under the control of a
160-kb fragment of the hPRL gene locus display a greater
transcriptional response to estrogen than the 5-kb pro-
moter construct (1). Either the known 1189 ERE is a
crucial response element and full transcriptional activa-
tion in response to 17-estradiol (E2) depends on
genomic context and other enhancer elements, or there
are additional upstreamEREs that contribute to the hPRL
E2 response. To test this hypothesis we have used BAC-
recombineering to mutate 4 base pairs of the1189 ERE
in the hPRL BAC construct (hPRL ERE-Mut BAC). Here,
we report that GH3 cells stably transfected with this con-
struct have significantly reduced estrogen sensitivity com-
pared with those stably transfected with the hPRL BAC,
suggesting that even in the large 160-kb genomic frag-
ment, this proximal ERE is the dominant response ele-
ment involved after E2 treatment. Additionally, we show,
using real-time bioluminescence imaging of hPRL ERE-
Mut directed Luc activity in single transfectant cells that
pulsatile cycles of hPRL transcription persist and are




The PRL-Luc reporter BAChas been previously described (1)
In order tomutate the previously defined ERE (9), the hPRL-Luc
BAC was maxiprepped using Macherey-Nagal Nucleobond
BAC100 kit (Thermo Fisher) and 100 ng used to transform
SW102 Escherichia coli cells by electroporation (1.8 kV, 200,
25 mF). Clones were selected, miniprepped, and assayed by
pulsed field gel electrophoresis with SalI and NotI digestions to
isolate a SW102-Prl-Luc positive clone. Seamless recombination
to mutate the ERE was achieved using methods described by
(24). Briefly, chimeric PCRwas used to amplify a homology arm
tagged GalK expression cassette (H-GalK-H) and used in pri-
mary recombination (positive clones selected on galactose con-
taining minimal media) to replace the wild-type (WT) ERE se-
quence. A second round of recombination with the same
homology arms flanking a mutated ERE sequence amplified
from vector phPrl5000mutERE (9) was performed (positive
clones selected on deoxygalactose and glycerol containing min-
imal media). Clones were screened by amplification of the ERE
region and subsequent EocNI digest of amplicon (the mutation
results in the formation of this restriction site). BAC DNA was
also digested with appropriate restriction enzymes and pulsed
field gel electrophoresis confirmed overall BAC size and struc-
ture was maintained.
Primers were as following: chimeric EREmutGalK-F (GalK-
specific sequence in bold) ATTCATTATAGTCATTTCATTT
AGGAAATTTCCAAAAGGTGAATGGAATTTTTAAGCCC
ATGAAAGATGAATTTTCCTGTTGACAATTAATCATCGG
CA, chimeric EREmutGalK-R CAAGGATAGCAGTGTGT
AAACTGTTATTAACTTATGATCTCTCTACCTTCTCTGA
CCCTGAGCCACTCTGAGGCCTCAGCACTGTCCTGCTCC
TT, hPrlmutERE-F AGGCTGCTTTAGATGCATGG, and hPrl-
mutERE-R GTTTTCCAGGGCAAACACAC.
Cell culture and generation of stable transfectant
BAC cell lines
Cells were maintained in phenol red-free DMEMwith pyru-
vate (Gibco) and supplemented with 1% glutamine and 10%
fetal bovine serum (Gibco). Serum starving conditions (hor-
mone free) for 24 hours were phenol red-free DMEM with py-
ruvate (11880; Gibco) supplemented with 1% glutamine and
0.25% BSA. With the exception of FGF-2 (Merck Biosciences)
and E2 (Abcam), all reagents were obtained from Sigma.
For the generation of the ERE-WT and ERE-Mut hPRL-Luc
BAC cell lines, 5 106 GH3 cells were seeded into 10-cm dishes
and left to adhere overnight. BAC DNA was prepared by
maxiprep (BAC100 Nucleobond kit; Macherey-Nagel), and 3
g were used to transfect 5  106 cells in a 10-cm dish using
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ExGen500 transfection reagent. Media were changed 3 days
after transfection and supplemented with 500-g/mL G418.
Media and antibiotic were refreshed every 3–4 days. Colonies
formed 2–3 weeks after culturing in selection media were ring
cloned into individual wells of a 48-well plate and sequentially
scaled up to large culture vessels as necessary. The clones were
screened for Luc expression and responses to stimuli (10nM E2,
5M forskolin [FSK], 10-ng/mL FGF-2, 10nM dexamethasone
[Dex], and 10-ng/mL TNF).
Endpoint luminometry assays
1  105 GH3 cells per well were seeded into 24-well plates,
serum starved for 24 hours, then stimulated in triplicate as in-
dicated. After treatment medium was removed, cells washed
once with PBS, then lysed with 200 L of lysis buffer per well
(25mM Tris/PO4, 10mM MgCl2, 5mM EDTA, 15% glycerol,
0.1% Triton X-100, and 0.1-mg/mL BSA). Cell lysis was aided
by agitation at room temperature for 15 minutes, ATP added to
a final concentration of 1mM, and Luc activity of samples mea-
sured using a FLUOstar Omega (BMG Labtech). Experiments
were performed in triplicate at least 3 times. Results are shown
as mean fold induction relative to an unstimulated control SD
of at least 3 independent experiments. For statistical analysis, P
values were calculated using Student’s t test.
Live-cell luminometry assays
1.5 104 GH3 cells per well were seeded into white opaque
96-well microplates (PerkinElmer), serum starved for 24 hours
in media containing 1mM luciferin, then stimulated in triplicate
as indicated. Microplates were covered with Breathe-Easy seal-
ingmembranes (Sigma) and Luc activity of wells measured using
a FLUOstar Omega (BMG Labtech) over a 24-hour period with
cells maintained at 37°C with 5%CO2-95% air. Photon counts
for each well were integrated over 5 seconds and repeated every
15minutes. Results are shown asmean fold induction relative to
an unstimulated control  SD of at least 3 independent exper-
iments. For statistical analysis, P values were calculated using
Student’s t test.
Real-time luminescence imaging
1.2  105 GH3 cells were seeded in
35-mm glass coverslip-based dishes
(Greiner), cultured in media containing
1mM luciferin. Luciferin was added at
least 12 hours before the start of the ex-
periment. Cells treated with 10-ng/mL
TNF or 10nM E2 were maintained in
hormone-free media for 24 hours before
stimulation. Cells were transferred to
the stage of a Zeiss Axiovert 200
equipped with an XL incubator (main-
tained at 37°C in a 5% CO2-95% air in
humidified conditions) in a dark room.
Luminescence images were collected us-
ing a Fluar 10, 0.5-NA objective
(Zeiss), and captured using a photon-
counting charge coupled device camera
(Orca II BT; Hamamatsu Photonics). Se-
quential images were taken with a 10-
minute integration period, then ana-
lyzed using Kinetic imaging software
AQM6 (Andor).
Stochastic switch model (SSM) analysis
Raw luminescence data was analyzed using a SSM to esti-
mate the probability of switches between variable transcription
rates (described in Ref. 26). This highly iterative reverse jump
Markov chainMonte Carlo algorithm back-calculates from ob-
served Luc activity using known protein and mRNA degrada-
tion rates producing a probability distribution of transcription
phase durations. Matlab 2014a software (MathWorks), includ-
ing the Bioinformatics and Statistical toolboxes were used for
mathematical analyses.
Results
Mutation of the 1189 ERE in the hPRL BAC-Luc
construct (ERE-Mut BAC-Luc)
The hPRL-Luc reporter BAC (hPRL BAC-Luc) has
been described previously. This reporter construct con-
tains approximately 115 kb of 5-flanking sequence from
the hPRL genomic locus, including the previously char-
acterized ERE at1189 bp (1). Using BAC recombineer-
ing we have mutated 4 conserved base pairs of the1189
ERE in the hPRL BAC-Luc construct (Figure 1, A and B,
and Supplemental Figure 1, A–C) to disrupt the sequence
and ER binding. Stably transfected pituitary GH3 clonal
cell lines expressing either hPRL ERE-Mut BAC-Luc
(here termed ERE-Mut) or hPRL WT-ERE BAC-Luc
(here termed ERE-WT) were then generated and clonal
lines screened for basal Luc activity to select for positive
transfectant clones.
Mutation of the 1189 ERE significantly reduces
estradiol-mediated activation of hPRL transcription
The estrogen responsiveness of 5 ERE-Mut and 5
ERE-WT cloneswere compared. Cells weremaintained in
Figure 1. Mutation of the 1189 ERE in the hPRL BAC-Luc construct (ERE-Mut BAC).
Mutagenesis schematic of the 1189 ERE mutation in the hPRL-Luc BAC construct. GalK-
mediated recombination was used to mutate 4 base pairs in the ERE, introducing an EcoNI site
(A). Sequencing confirmation of the 4 base pair mutations in the 1189 ERE, ERE-WT top line,
ERE-Mut bottom line (B).
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hormone-free medium for 24 hours, treated with 10nM
E2 (Figure 2A), then lysed and Luc activity measured. All
5 ERE-WT and 3 of the ERE-Mut clones showed a sig-
nificant induction in reporter gene activity after E2 treat-
ment. However, ERE-Mut clones all showed significantly
reduced transcriptional activity compared with their
ERE-WT counterparts, with a mean fold induction of 1.6
compared with a 4.2-fold mean induction, respectively.
Cell proliferation assays showed a small but nonsignifi-
cant increase in cell number over the 24-hour period after
E2 treatment (data not shown). Estrogen activation of the
endogenous rat PRL (rPRL) promoter has previously
been shown in both the GH3 cell line and primary cul-
tures of Fischer-344 rat pituitary glands, with a 4-fold
activation observed in both using quantitative PCR after
a 24-hour exposure to 10nM E2 (9).
Additional experiments were then carried out on 2
selected GH3 stable transfectant clonal lines, ERE-WT1
and ERE-Mut3. Cotreatment of E2with the anti-estrogen
4-hydroxy-tamoxifen (4-OHT) abolished E2-mediated
reporter gene expression in both ERE-WT and ERE-Mut
cell lines, suggesting ER involvement in the inductions
seen (Figure 2B). Real-time live-cell luminometry of cell
populations after treatment with increasing concentra-
tions of E2 (0.01nM–1000nM) over time showed a pro-
gressive, dose-dependent increase in reporter gene expres-
sion in both cell lines but with significantly reduced
transcriptional activity observed in ERE-Mut3 compared
with ERE-WT1 (Figure 2, C and D).
Pulsatile cycles of hPRL gene transcription are
independent of ER binding
The transcriptional activity of the hPRL gene is highly
dynamic and pulsatile. Time lapse observations of hPRL
reporter gene expression in pituitary cell lines and pri-
mary cells have found asynchronous cycles of transcrip-
tion (25, 27–29), whichwe have proposed to be caused by
phases of chromatin remodeling (30). Such patterns of
gene expressionmay be caused by stochastic regulation of
intracellular processes such as transcription factor bind-
ing, with cyclical binding leading to the ordered recruit-
ment of cofactors to the promoters of target genes (12,
31–33). In addition binding of ER at the rPRL locus has
been implicated in chromatin remodeling and also in
DNA looping (17, 34). To assess whether stochastic reg-
ulation of ER binding to the 1189 ERE plays a critical
role in determining patterns of hPRL promoter activity
we measured hPRL promoter-directed Luc expression in
single ERE-Mut3 and ERE-WT1 transfectant cells (Fig-
ure 3). Transcription cycle characteristics were examined
Figure 2. Estrogen responsiveness of ERE-WT and ERE-Mut BAC cell lines. E2 stimulation (10nM) of 5 individual serum-starved (24 h) ERE-WT
and ERE-Mut clones; after treatment for 24 hours with either 10nM E2 or vehicle control (0.1% dimethylsulfoxide [DMSO]), cells were lysed and
assayed for Luc activity; **, P  .001 (A). Effect of E2 cotreatment with the E2 antagonist 4-OHT (1000nM) in ERE-WT1 and ERE-Mut3 cell lines
(B). Live cell luminometry of serum-starved (24 h) ERE-WT1 (C) and ERE-Mut3 (D) cell lines using increasing concentrations of E2 with Luc activity
measured every 15 minutes. The dotted line indicates the baseline determined from untreated control samples. Results are shown as fold
induction  SD from the untreated control sample with values representing the mean of at least 3 independent experiments, each with 3
replicates.
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Figure 3. Single cell transcriptional activity in ERE-WT and ERE-Mut BAC cell lines. Luminescence signal from ERE-WT1 and ERE-Mut3 BAC cell
lines in serum containing media. Representative images of ERE-WT1 and ERE-Mut3 BAC cells, white line represents scale bar equal to 50M (A).
Single cell transcriptional traces from unstimulated ERE-WT1 (B) and ERE-Mut3 BAC cells (C) in serum containing media. Luminescence signal from
serum-starved ERE-WT1 cells: representative images after 10nM E2 treatment (D) and single cell transcriptional traces from untreated (E) and
10nM E2-treated cells (F). Luminescence signal from serum-starved ERE-Mut3 cells. Representative images after 10nM E2 treatment (G) and single
cell transcriptional traces from untreated (H) and 10nM E2-treated cells (I). Colored lines represent data from single cells with the thick black line
representing the mean population response; n 	 21 cells (E), n 	 19 cells (F), n 	 22 cells (H), and n 	 18 cells (I).
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in 3 different conditions; serum containing media (Figure
3, A–C) and serum-free media with or without estradiol
(Figure 3, D–H).We found that pulsatile patterns of tran-
scription persisted in ERE-Mut3 cells (Figure 3, A, C, and
G) and that characteristics were comparable with those
observed in ERE-WT1 cells (Figure 3, A, B, and E) in both
serum-free and serum containing media. The mean cycle
length was determined and found to be 8.9 hours (3.3 h
SD) and 7.5 hours (2.2 h SD) for ERE-Mut and
ERE-WT cells, respectively, when cultured in serum con-
taining medium (Figure 4, A–C). These data fit well with
our previous analysis of cycle length using the 160-kb
hPRL promoter reporter construct where a mean cycle
length of approximately 9 hours was observed (30). Ad-
ditionally, mathematical analysis of single cell lumines-
cence data using a SSM to estimate transcriptional switch
timings (26), also predicted comparable cycle length times
(Figure 4, D and E). These data suggest that hPRL cyclical
transcription is not reliant on ER binding and supports
our previousmechanistic model describing the generation
of hPRL transcription cycles (30). Additionally, real-time
single-cell luminescence imaging of serum-starved cells
after E2 stimulation showed increased amplitude of tran-
scription cycles in ERE-WT1 cells leading to a progressive
increase over time in reporter gene expression which was
not observed in ERE-Mut3 (Figure 3, E and H). This
further supports the importance of the1189 ERE in the
estrogen responsiveness of the hPRL promoter.
A biphasic hPRL transcriptional response to TNF
is abolished in ERE-Mut cell lines
PRL promoter activation by TNF is mediated by the
nuclear factor-B (NF-B) signaling pathway and has
previously been shown to have a biphasic effect over 5–24
hours using a 5-kb hPRL-Luc reporter construct (35).
Mutation of the 1189 ERE in the 5-kb construct abol-
ished the responsiveness of the hPRL promoter to TNF
treatment and our previous work indicated that com-
bined estrogen and TNF exerted cooperative stimula-
tion of the hPRL gene (9). To determine the effect of this
mutation on the TNF response of the entire hPRL locus,
4 ERE-WT and 4 ERE-Mut clonal cell lines were treated
with 10-ng/mLTNF and Luc activity measured 5 and 24
hours after treatment (Figure 5A). A significant decrease
in the acute transcriptional response at 5 hours was ob-
served in the ERE-Mut cell lines compared with ERE-WT
with a mean fold induction of 1.5 compared with 2.4,
respectively. No significant difference was observed in the
later transcriptional activation between cell lines.
Real-time live-cell luminometry of ERE-Mut3 and
ERE-WT1 clones confirmed the TNF-induced biphasic
transcriptional response in the ERE-WT1 cell line with an
acute increase in hPRL-directed Luc expression observed
at 2–6h and a later response 12–24 hours after treatment
(Figure 5B). This biphasic responsewas abolished in ERE-
Mut3 BAC cell line (Figure 5B), in which the early re-
sponse was lost but the late activation remained 24 hours
after TNF treatment. Real-time single-cell biolumines-
cence imaging confirmed the same pattern of hPRL tran-
scriptional activation after TNF treatment with loss of
the acute transcriptional response observed in ERE-Mut3
cells (Figure 5C).
Cotreatment of ERE-WT cells with 4-OHT caused sig-
nificant inhibition of both acute and late TNF induced
hPRL Luc activity, whereas in ERE-Mut cells no differ-
ence was observed (Figure 5D). This suggests that ER
activity at the1189 ERE plays a critical role in the acute
transcriptional effect of TNF for this gene. Control ex-
periments showed that the hPRL FSK response was not
impaired by the ERE mutation and that cotreatment with
4-OHT did not affect transcriptional activity in either cell
line (Figure 5E).
Responses of ERE-Mut and ERE-WT cell lines to
well-characterized hPRL regulating stimuli
In addition to the classic genomic action of ligand ac-
tivated ER, the ER can also regulate gene transcription in
a number of other ways. Activation of kinase signaling
cascades by growth factors and cytokines can phosphor-
ylate and activate ER, leading to recruitment to EREs and
subsequent changes in gene expression (14). To determine
whether the 1189 ERE plays a role in the hPRL tran-
scriptional response to other stimuli we compared the
responses of 4 ERE-WT and 4 ERE-Mut clonal cell lines
after treatment with a range of well-know hPRL regulating
stimuli, including FSK, phorbol myristate acetate (PMA),
FGF-2, andDex. The transcriptional response to these stim-
uli was not compromised by the ERE mutation. Compari-
son of the mean response of clonal cell lines found no sig-
nificant difference in reporter gene expression between
ERE-WTand ERE-Mut cell lines (Figure 6, A and B, respec-
tively) implying the1189ERE region is not involved in the
hPRL transcriptional response to these stimuli.
Discussion
Regulatory DNA elements can be situated distant from
the transcription start sites of the genes they regulate and
throughmechanisms such as chromatin looping these dis-
tal enhancer or silencer regions can be brought into con-
tact with proximal promoter regions to directly influence
transcriptional activity (36). The use of BAC reporter
constructs in molecular physiology enables the inclusion
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Figure 4. PRL promoter transcription cycle length comparison of ERE-WT1 and ERE-Mut3 BAC cell lines. Representative images from ERE-Mut3
cell over time (A). Promoter activity from ERE-WT1 and ERE-Mut3 cell lines. Each line represents the transcriptional activity from a single cell with
the first peak of each cell aligned to 0 (B). Mean cycle lengths are compared between ERE-WT1 and ERE-Mut3 cell lines. Bars show SD from 13
and 15 cells, respectively, from 3 experiments per cell type (C). SSM example traces from ERE-WT1 and ERE-Mut3 cell lines showing estimated
temporal switches between variable transcription rates (blue) when back calculated from observed luminescence (green). A cycle (black arrow) was
determined as the duration from the first decrease in rate to the next decrease in rate having followed an intermittent increase. D, Estimated cycle
length determined from SSM, compared between ERE-WT1 and ERE-Mut3 cell lines. Bars show SD of this cycle length from 10 and 21 cells,
respectively, in 3 experiments per cell type (E).
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of large regions of flanking DNA and BAC recombineer-
ing allows the identification of possible long-range regu-
latory regions which can influence gene transcription.We
have previously generated a BAC-reporter gene construct
expressing Luc under the control of 163 kb of the hPRL
locus (hPRL-BAC-Luc). Using the hPRL BAC-reporter
gene construct we have studied hPRL gene expression
under different physiological conditions in both stably
transfected GH3 pituitary cell lines and primary pituitary
cells from transgenic rats (1, 2, 27, 37). Here, we have
further engineered the hPRL-BAC construct to determine
the potential contribution of extended genomic regions to
the estrogen responsiveness of the hPRL promoter,
whether the 1189 ERE is crucial, and its function de-
pends on genomic context and other enhancer elements or
there are additional more distal ERE’s involved in the
hPRL E2 response. Using a GalK strategy (24), we have
mutated the previously defined variant1189 ERE in the
hPRL-BAC-Luc construct and compared the response of
stable cell lines expressing these constructs (ERE-WT and
ERE-Mut) to a range of well-characterized hPRL regulat-
ing stimuli. Mutation of the 1189 ERE dramatically
altered the promoter’s responsiveness not only to E2 but
also to TNF. Unexpectedly, disruption of this crucial
DNA element had no effect on the characteristic pulsatile
cycles of hPRL transcription, which were observed in
both ERE-WT and ERE-Mut transfectant cells.
Figure 5. TNF response of ERE-WT and ERE-Mut BAC-Luc cell lines. Luc activity after TNF stimulation (10-ng/mL) of 4 individual ERE-WT and 4
ERE-Mut clones measured at 5 and 24 hours after treatment; *, P  .05 (A). Time series live-cell luminometry of selected clones, ERE-WT1 and ERE
Mut-3 after 10-ng/mL TNF stimulation with readings taken every 15 minutes (B). Representative luminescence images of serum-starved ERE-WT1
and ERE-Mut3 cells after 10-ng/mL TNF treatment (C). Effect of ER inhibition on the TNF response of ERE-WT1 and ERE-Mut3 cells using
combined 4-OHT and TNF treatment; *, P  .05 (D). Effect of ER inhibition on the FSK response of ERE-Mut and ERE-WT cells using 4-OHT and
TNF combined treatment (E). Results are shown as fold induction  SD from an untreated control sample. Values represent the mean of at least
3 independent experiments, each with 3 replicates.
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Estrogen is an important physiological regulator of
PRL expression. It is known to increase lactotroph cell
growth and activate PRL gene expression both in vivo
using rodent models and in vitro in rat pituitary cell lines
and dispersed primary pituitary cell cultures (9, 11, 19,
38, 39). Transgenic mice carrying a BAC transgene con-
taining the entire hPRL locus exhibit tissue expression of
hPRL, which in pituitary lactotrophs is responsive both in
vivo and in vitro to E2 treatment (11). Continuous E2
treatment for 14 days via an implanted pellet led to sig-
nificantly increased pituitary weight and hPRL gene ex-
pression, and in vitro E2 treatment of primary pituitary
cell cultures from these animals led to increased hPRL
protein (11). Estrogen-mediated regulation of hPRL tran-
scription is facilitated by binding of ER to the 1189
ERE and induces modest reporter gene activation in
hPRL-Luc stable transfectant pituitary cells (5-kb hPRL-
Luc) (9). However, cells expressing Luc under the control
of a 160-kb fragment of the hPRL gene locus display a
significantly greater transcriptional response to E2 than
the 5-kb promoter construct (1). This implied that the
larger genomic fragment may contain additional sites in-
volved in estrogen-mediated activation of the hPRL gene,
either additional more distant EREs or other upstream
sequences required for the full responsiveness of the
known proximal ERE. The promoter regions of E2 re-
sponsive genes can contain numerous EREs (40, 41) and
transcriptional synergism after ER binding to multiple
EREs has been reported (41–43). Additionally, chromo-
some-wide identification of EREs in human and mouse
genomes found that EREs are frequently situated far dis-
tant from the genes they regulate (21, 44) with only 5%of
the mapped ERE-binding sites in MCF-7 cells found
within 5-kb region of the transcription start site (45). The
involvement of upstream sequences in estrogen-induced
transcriptional regulation of the rPRL promoter has also
been reported with chromatin looping mediated by the
1575 ERE suggested as a mechanism of E2-induced
transcription at the rPRL locus (34).
Analysis of the hPRL-BAC sequence for potential ERE
motifs was performed using Dragon ERE finder version 3
(46). This identified a number of potential long-range
EREs with 4 sites being within 1 kb of a forkhead box
protein A1 (FoxA1)-binding site (data not shown). This
“pioneer” factor is suggested to be required for long-
range gene activation, binding close to EREs to facilitate
ER binding (21). In addition, a functional ERE has been
identified in the hPRL distal promoter (approximately
6950 kb from the pituitary transcription start site), and
shown using promoter reporter constructs in T47D hu-
man breast cancer cells to induce hPRL promoter activity
in response to E2 (10). However, it is likely from our data
that any more distal, putative EREs have very little func-
tional effect in the estrogen-mediated activation of the
hPRL promoter. Mutation and subsequent loss of ER
binding to just the single 1189 ERE within the 160-kb
hPRL genomic fragment resulted in complete loss of sen-
sitivity to E2 in 2 of the ERE-Mut transfectant clones
screened, and minimal induction in a further 3 lines, sug-
gesting that this relatively proximal ERE is the dominant
response element even in the context of the very large
genomic fragment. Furthermore, full estrogen-mediated
activation of the hPRL promoter in T47D cells did not
involve the 1189 proximal ERE but required the coop-
erative action of ERs on both ERE and AP-1 sites in the
Figure 6. Responses of ERE-Mut and ERE-WT cell lines to well-
characterized hPRL regulating stimuli. Stimulation of 4 individual
serum-starved ERE-WT (A) and ERE-Mut (B) cell lines (Fsk, 5M; FGF-2,
10 ng/mL; PMA, 10nM; Dex, 10nM). Luc activity was measured 24
hours after drug treatment. Results are shown as fold induction  SD
from an untreated control sample. Values represent the mean of at
least 3 independent experiments, each with 3 replicates. Each bar
represents an individual clone.
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distal promoter (10), suggesting different mechanisms in-
volved in the E2-mediated regulation of the hPRL pro-
moter in extrapituitary and pituitary cells. It is possible
that intrachromosomal interactions between this crucial
1189 ERE and an upstream enhancer region may be
responsible for the enhanced E2-mediated transcriptional
activation observed in cells transfected with the 160-kb
hPRL BAC compared with the 5-kb hPRL construct. This
hypothesis would require further work to test in detail,
application of circularized chromosome conformation
capture (4C) assays may identify unknown DNA regions
interacting with the 1189 ERE.
Interactions between the ER and NF-B signaling
pathways have been widely reported in multiple systems
with both positive and negative cross talk effects de-
scribed (47–50). Cooperative binding of both transcrip-
tion factors at adjacent response elements in the promoter
region of the ABCG2 gene stabilizes their interaction after
combined TNF and E2 treatment, leading to enhanced
expression of this estrogen responsive gene (48). Addi-
tionally, TNF can activate ER signaling in human endo-
metrial epithelial cells transfected with an ERE-Luc re-
porter, with a significant increase ERE transcriptional
activity observed after TNF treatment in the absence of
ligand (16). However, TNF had no effect on ERE tran-
scriptional activity in GH3 rat pituitary cells transfected
with a consensus ERE-Luc reporter (9), suggesting cell
type and/or species-specific differences in ER and NF-B
signaling cross talk.
Using a 5-kb hPRL-Luc reporter, we have previously
shown that the presence of the 1189 ERE region is
essential for TNF-mediated activation of the hPRL pro-
moter, measured 24 hours after TNF treatment (9). In
the present study, we show that mutation of this ERE in
the 160-kb hPRL BAC results in loss of the acute TNF
transcriptional response, but no significant effect on the
later, 12- to 24-hour transcriptional activation. Cotreat-
ment of ERE-WT cells with 4-OHT significantly reduces
the acute hPRL transcriptional TNF response to levels
comparable with ERE-Mut cells, indicating ER activity
at the 1189 ERE is essential for the ability of TNF to
acutely enhance hPRL gene expression. The absence of
any difference in the later, more delayed TNF transcrip-
tional response between ERE-Mut and ERE-WT hPRL
BAC cell lines suggests that this slower response is likely
to be mediated by upstream regulatory regions contained
in the extended genomic sequence, not present in the 5-kb
hPRL promoter construct.
The hPRL promoter region contains multiple response
elements, binding transcription factors involved in both
positive and negative regulation of the gene. These in-
clude binding sites for pituitary-specific transcription fac-
tor 1 (Pit1) (51, 52), AP-1 (10, 53), E26 transformation-
specific (ETS) domain factors (ETS-1) (54) in addition to
the 1189 ERE. The hPRL 1189 ERE is a putative
critical response element which could have contributed to
the transcriptional response to other hPRL regulating
stimuli. However, treatment of multiple ERE-WT and
ERE-Mut clonal cell lines with FSK, FGF, PMA, andDEX
revealed that there was no significant difference in the
transcriptional response to these stimuli between the 2
cell lines after treatment for 24 hours (Figure 6, A and B).
This indicates that the 1189 ERE is not involved in the
transcriptional response to these stimuli.
Cyclical, dynamic patterns of hPRL gene expression
over time have been shown using real-time biolumines-
cence and fluorescence imaging of hPRL-BAC (1, 27) and
hPRL-5-kb (25, 28–30) reporter constructs to visualize
hPRL promoter directed reporter gene activity in individ-
ual living cells (30). Additionally, pulsatile patterns of
hPRL gene expressionwere observed in both adenovirally
transduced GH3 and primary Syrian hamster pituitary
cells, using an adenoviral vector expressing Luc regulated
by the hPRL promoter. Dynamic hPRL transcriptional
activity was observed in both the clonal cell lines and in
primary cells (28). In all of the model systems that have
been studied, heterogeneous, dynamic cycles of hPRL
transcription have been observed, showing that the re-
sponses are not affected by construct type, promoter
length or site of integration. This phenomenon appears to
be a fundamental property of the transcription process
with transcriptional bursting observed from numerous
mammalian genes (55).
Analysis of ER binding to the proximal promoter
regions of several estrogen responsive genes has shown
cyclical recruitment after E2 treatment with subsequent
ordered recruitment of cofactors to the target genes (12,
17, 20). This mechanism has been proposed to be a gen-
eral property of ER regulated genes. Given the cyclical
nature of hPRL gene transcriptional activity and its estro-
gen responsiveness we hypothesized that cyclical binding
of ER to the degenerate ERE may play a critical role in
generating the cycles or bursts of transcriptional activity.
Surprisingly real-time bioluminescence imaging of single
clonal ERE-Mut transfectant cells showed that oscillatory
patterns of transcription persisted, with cycle lengths
comparable with those observed in ERE-WT clonal cell
lines (Figure 4). This suggests that cyclical fluctuations of
promoter activity are a fundamental feature of the tran-
scription complex, at least at this locus, and that they are
not dependent upon ER binding or activity. This supports
our previous mechanistic model of hPRL transcription,
proposing that chromatin remodeling processes, rather
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than individual endocrine signals, generate on and off
cycles of transcription (30).
In summary, we have used BAC recombineering to
identify the critical role of a single, relatively proximal
ERE in controlling PRL transcription. This ERE controls
not only the response to estrogen but also the transcrip-
tional response to TNF. Crucially, we have used real-
time bioluminescence imaging of transfectant cells to re-
veal that cycles of transcriptional activation in individual
living cells are maintained despite the disruption of this
key ERE. This indicates that transcriptional cycles are
independent of ER binding and activation and are not
directly controlled by hormonal signaling.
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